Citation for published version (APA):

Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher’s definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher’s website for any subsequent corrections.

General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the Research Portal

Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Proteomic analysis reveals an altered protein composition of subcutaneous adipose tissue in patients with chronic kidney disease

Joanna Gertow, PhD, Chang Zhi Ng, BSc, Rui Miguel Mamede Branca, PhD, Olivera Werngren, MSc, Lei Du, PhD, Sanela Kjellqvist, PhD, Peter Hemmingsson, MD, PhD, Annette Bruchfeld, MD, PhD, Helen MacLaughlin, PhD, Per Eriksson, PhD, Jonas Axelsson, MD, PhD, Rachel M. Fisher, PhD

PII: S2468-0249(17)30314-5
DOI: 10.1016/j.ekir.2017.07.007
Reference: EKIR 199

To appear in: Kidney International Reports

Received Date: 20 January 2017
Revised Date: 30 June 2017
Accepted Date: 24 July 2017


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Proteomic analysis reveals an altered protein composition of subcutaneous adipose tissue in patients with chronic kidney disease

Running title: Adipose tissue in chronic kidney disease

Joanna Gertow¹; PhD, Chang Zhi Ng¹, BSc, Rui Miguel Mamede Branca², PhD, Olivera Werngren¹, MSc, Lei Du¹, PhD, Sanela Kjellqvist³, PhD, Peter Hemmingsson⁴, MD, PhD, Annette Bruchfeld⁴, MD, PhD, Helen MacLaughlin⁵, PhD, Per Eriksson¹, PhD, Jonas Axelsson⁶, MD, PhD and Rachel M. Fisher¹*, PhD

¹Cardiovascular Medicine Unit, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; ²Clinical Proteomics Mass Spectrometry, Department of Oncology-Pathology, Science For Life Laboratory and Karolinska Institutet, Stockholm, Sweden; ³Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Stockholm, Sweden; ⁴Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden; ⁵Division of Diabetes and Nutritional Sciences, King’s College London and King’s College Hospital, London, United Kingdom; ⁶Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

*Corresponding author: Rachel M Fisher, Cardiovascular Medicine Unit, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital (L8:03), 171 76 Stockholm, Sweden.

E-mail: rachel.fisher@ki.se; Phone: +46-8-51773245; Fax: +46-8-311298

Key words: chronic kidney disease, adipose tissue, cardiovascular disease, vimentin, alpha-1-microglobulin/bikunin precursor, proteomics

Word count abstract: 246

Word count main text: 3661
Abstract

Introduction

Loss of renal function is associated with high mortality from cardiovascular disease (CVD). Patients with chronic kidney disease (CKD) have altered circulating adipokine and non-esterified fatty acid concentrations and insulin resistance, which are features of disturbed adipose tissue metabolism. Since dysfunctional adipose tissue contributes to the development of CVD, we hypothesize that adipose tissue dysfunctionality in patients with CKD could explain, at least in part, their high rates of CVD. Therefore we characterised adipose tissue from patients with CKD, in comparison to healthy controls, to search for signs of dysfunctionality.

Methods

Biopsies of subcutaneous adipose tissue from 16 CKD patients and 11 healthy controls were analysed for inflammation, fibrosis and adipocyte size. Protein composition was assessed using two-dimensional gel proteomics combined with multivariate analysis.

Results

Adipose tissue of CKD patients contained significantly more CD68-positive cells, but collagen content did not differ. Adipocyte size was significantly smaller in CKD patients. Proteomic analysis of adipose tissue revealed significant differences in the expression of certain proteins between the groups. Proteins whose expression differed the most were alpha-1-microglobulin/bikunin precursor (AMBP, higher in CKD) and vimentin (lower in CKD). Vimentin is a lipid droplet-associated protein and changes in its expression may impair fatty acid storage/mobilisation in adipose tissue, while high levels of AMBP may reflect oxidative stress.

Conclusion

These findings demonstrate that adipose tissue of CKD patients shows signs of inflammation and disturbed functionality, thus potentially contributing to the unfavourable metabolic profile and increased risk of CVD in these patients.
Introduction

Chronic kidney disease (CKD) is a global health problem with increasing prevalence and poor outcome,\(^1\) where cardiovascular disease (CVD) accounts for up to 50% of all-cause mortality.\(^2\) The reason for the high CVD risk is unclear, but cannot be explained simply by a decrease in filtering capacity of the kidneys. Indeed patients with a functioning kidney transplant still maintain higher CVD risk than the general population.\(^3\) Thus the cause of the metabolic dysregulation observed in CKD is complex, but a role for adipose tissue has been suggested.

Adipose tissue buffers circulating non-esterified fatty acid (NEFA) concentrations, with a failure to do so leading to the development of an atherogenic dyslipidemia\(^4\) and lipotoxicity, which results in deterioration of tissue function and impaired lipid and glucose utilization.\(^5,6\) Adipocyte hypertrophy (increased cell size) is often followed by development of tissue fibrosis, hypoxia and secretion of pro-inflammatory cytokines (such as TNF or IL-6) triggering inflammatory cell recruitment and deterioration of insulin signalling\(^7\) making adipose tissue dysfunctional. Malfunctioning adipose tissue contributes to the development of CVD locally and systemically. Local effects relate mainly to the direct impact on the vessel wall of fatty acids (FA) and adipokines released by perivascular adipose tissue, promoting expression of adhesion molecules, inflammatory cytokines and coagulation factors by endothelial cells\(^8,9\) and induce proliferation and migration of vascular smooth muscle cells (VSMC) and macrophage infiltration\(^10,11\) and inflamed visceral fat can directly promote atherosclerotic lesion development in the underlying vessel\(^12\). Systemic effects are attributed to both subcutaneous and visceral depots. Since the subcutaneous abdominal depot is the major determinant of circulating NEFA concentrations,\(^13\) its perturbed function promotes development of a pro-atherogenic lipoprotein profile. Furthermore, a shift towards secretion of a more pro-inflammatory adipokines by subcutaneous and/or visceral adipose tissue promotes VSMC migration, proliferation, osteogenic differentiation, induces a pro-thrombotic phenotype in vascular endothelial cells and upregulates mediators of vascular inflammation, like TNF, IL-2, IL-6 and CCL2.\(^14,15\)

Malfunctional adipose tissue is believed to promote CVD via the mechanisms described above. Although it is unknown whether these pathways are important contributors to the high rates of CVD in CKD patients, the hypothesis has been proposed.\(^16-21\) The supporting data include the observation that
CKD patients have elevated NEFA concentrations - an independent predictor of all-cause and cardiovascular death.\textsuperscript{21} Furthermore, CKD patients have perturbed circulating adipokine concentrations\textsuperscript{18,20} and increased systemic inflammation that correlates with fat mass.\textsuperscript{16} Indeed, visceral fat mass in peritoneal dialysis patients is an independent predictor of vessel dysfunction and therefore a risk factor for CVD.\textsuperscript{17} Unfavourable changes in markers reflecting oxidative stress, inflammation and impaired vessel function have been reported in subcutaneous adipose tissue of patients with kidney failure.\textsuperscript{22,23} Furthermore, a uremic milieu increases basal lipolysis rates and decreases expression of the lipid droplet-associated protein perilipin in primary adipocyte cultures,\textsuperscript{19} which could lead to increased FA release. Finally, adipose lipoprotein lipase activity is decreased in CKD patients leading to the formation of lipoproteins with a pro-atherogenic lipid composition.\textsuperscript{24} Thus a range of studies have suggested that uremic adipose tissue may be dysfunctional, which could position adipose tissue as a contributing factor to the development of CVD in CKD patients. However a beneficial role of adipose tissue in CKD has also been suggested\textsuperscript{25} with high BMI being associated with better outcome in CKD patients,\textsuperscript{25,26} but this was true only when accompanied by normal or high muscle mass, indicating that any beneficial role of obesity is likely attributable to lean mass rather than adipose tissue.

Many of the studies that indicate a role for adipose tissue in the development of CVD associated with CKD are based on systemic analyses, while direct analysis of adipose tissue, especially protein analysis, is largely lacking. Therefore we describe a proteomic approach to characterise the protein composition of subcutaneous adipose tissue in CKD patients, with the aim of better understanding if adipose tissue is dysfunctional and could contribute to the increased risk of CVD in patients with kidney failure.
Materials and Methods

Subjects

16 subjects with stage 5 CKD (recipients of kidney transplantation) and 11 healthy individuals (kidney donors) were enrolled in the study performed at Karolinska University Hospital (Huddinge). The number of subjects included in the different analyses varied and is indicated accordingly (Table 1). Inclusion criteria were: age 18-75 years and BMI 18-30 kg/m². Exclusion criteria were: hypersensitivity for Xylocain®, treated diabetes, and ongoing treatment with heavy immunosuppressives (such as cortisone). Of the 16 CKD patients prior to kidney transplantation, 7 had received haemodialysis (3.5-4 hours, 3-4 times per week, urea reduction rate >80%), 3 received peritoneal dialysis, 2 received both types of dialysis and 4 had no previous dialysis treatment. The study was approved by the Stockholm Regional Ethics Committee and conducted according to the principles of the Declaration of Helsinki. All patients gave their written consent.

Subcutaneous adipose tissue biopsies from the lower abdominal area were collected during kidney transplant surgery from both kidney recipients and donors. One part of the tissue was fixed and embedded in paraffin for histological analysis and one part was placed in AllProtect® Reagent (Qiagen) and stored at -20°C for subsequent proteomic analysis. Fasting blood samples were collected one day before the operation and analysed using accredited methods in the clinical chemistry laboratory at Karolinska University Hospital.

A separate group (n=9, 1 male and 8 females, age 48.3±7.5 years, 2 patients had diabetes and all had hypertension) of morbidly obese (BMI 41.2±4.4kg/m²) CKD patients (CKD stage 3-5) admitted to King's College Hospital, London, UK for bariatric surgery was enrolled in the study. Subcutaneous adipose tissue biopsies from the abdominal region were collected during surgery and stored in AllProtect® Reagent (Qiagen) at -20°C. These biopsies were used for proteomic analysis only. The study was approved by the British National Health Service Research Ethics Committee (NHS REC) and the use of biopsies in Sweden was approved by the Stockholm Regional Ethics Committee. All patients gave their written consent.

Histological analyses
Five µm paraffin sections were used for histological analyses. For analysis of inflammation, a mouse CD68 (NCL-CD68-KP1, 1:200, Leica Biosystems Newcastle Ltd., Newcastle Upon Tyne, UK) antibody was used. Sections were counterstained with Harris hematoxylin (Histolab, Gothenburg, Sweden). Numbers of positive cells were counted in one entire section of each adipose tissue biopsy on two occasions by two independent observers who were blinded as to the sample status. These numbers were normalized for the total tissue area, measured using the ImageJ application (ImageJ 1.48 [imagej.nih.gov/ij]). For evaluation of fibrosis, adipose tissue sections were stained with saturated picric acid containing 0.1% picrosirius red (Direct Red 80, Fluka), scanned (Hamamatsu NanoZoomer-XR Digital slide scanner C12000) and visualized using Nano Zoomer Digital Pathology viewer software (U12388-01; NDP.view2 Viewing). Representative picrosirius red stainings of a control individual and a CKD patient are shown in Supplemental Figure 1. Collagen content was calculated as the percentage of the total section area. Adipocyte size was measured using the ImageJ application according to the method described previously. Representative images of ImageJ-transformed pictures from a control individual and a CKD patient used for size quantification are shown in Supplemental Figure 2.

Proteomics

Protein extraction, two-dimensional electrophoresis, scanning, analysis and protein identification with tandem mass spectrometry (LC-MS/MS) were performed as described previously. Proteins were extracted from approximately 200mg of adipose tissue. For analytical gels, 5µg of CyDye-labelled total protein was loaded on each gel. The preparative gel was loaded with 1mg of internal standard (a mixture of adipose tissue protein extracts from all individuals pooled together) and stained with Pierce™ Silver Stain for Mass Spectrometry. Mass spectrometry analysis was performed by the Clinical Proteomics Mass Spectrometry facility, Karolinska Institutet/ Karolinska University Hospital/ Science for Life Laboratory.

Western Blot

Protein samples (20 µg) were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad). After incubation with 5% nonfat milk in a mixture of Tris-Buffered Saline
and Tween 20 the membrane was incubated with anti-vimentin (SC-66002, 1:500, Santa Cruz Biotechnology, Santa Cruz) or anti-AMBP (SC-81948, 1:400, Santa Cruz Biotechnology, Santa Cruz) antibody at 4 °C for 12 hours. Beta-actin was used as a loading control (1:250, Sigma Aldrich). Membranes were then incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies (1:50000, Bio-Rad) and developed with ECL Prime (GE Healthcare, Little Chalfont, UK). Detection was performed with X-ray film Agfa CP-BU new (Agfa Healthcare, Mortsel, Belgium).

7 Statistical analysis

Comparisons between CKD patients and healthy controls were performed using a Student's t-test for continuous variables or Pearson's Chi-squared test with Yates’ continuity correction for gender distribution. Differences in CD68 positive cell count, collagen content and adipocyte cell size between groups were compared using a Mann Whitney U-test. Comparison of protein spot volumes between controls, lean CKD and obese CKD patients was performed using ANOVA and Fisher’s LSD post-hoc tests. ANCOVA was employed to test for differences in adipocyte size between patients and controls with BMI as a covariate. The analysis of the proteomic data (202 distinct protein spots) was performed by multivariate analysis (orthogonal projections to latent structures discriminant analysis, OPLS-DA) as described previously.28
Results

We obtained subcutaneous abdominal adipose tissue from 16 patients with kidney failure (stage 5 CKD) and 11 healthy individuals (kidney donors). The CKD patients had significantly lower BMI than the control group and several blood markers reflecting kidney failure and related complications differed significantly between the groups, but age, gender distribution and glucose concentrations were not different (Table 1). Concentrations of triglyceride, total cholesterol and high-density lipoprotein cholesterol in the CKD patients were within normal ranges (Table 1).

Adipose tissue of CKD patients contains more CD68-positive cells and has smaller adipocytes than healthy controls

Patients with CKD had significantly more CD68-positive cells in their subcutaneous adipose tissue than controls (Figure 1A, 1B and 1C). To assess whether adipose tissue in patients with CKD was fibrotic we stained for collagen using picrosirius red (Supplemental Figure 1), but quantification of this staining revealed no significant difference between the groups (Figure 1D). Mean adipocyte size (calculated from tissue sections, Supplemental Figure 2) was significantly smaller in patients with CKD compared to healthy individuals (Figure 1E). This difference in adipocyte size was maintained even after correction for BMI (p=0.017, data not shown).

Proteomic analysis reveals differential protein composition in adipose tissue of healthy controls and patients with kidney failure

To evaluate whether adipose tissue protein expression patterns differed between individuals with and without CKD, protein extracts from 13 lean CKD patients and 7 control individuals were analysed using two-dimensional gel electrophoresis and a total of 202 distinct protein spots were observed (Figure 2). Spot volumes (corresponding to protein expression levels) were measured and used to create a multivariate model (OPLS-DA), which revealed a clear separation of the CKD patients and healthy controls, indicating significant differences in the expression of certain proteins (Figure 3A). A graphical representation of the contribution of the 202 protein spots to the separation between the CKD and the controls is shown in the loading plot (Figure 3B). Quality parameters indicating a robust OPLS-DA
model were as follows: number of principal components = 1+1, \( R_x^2 \) (explained variance) = 0.245, \( Q_y^2 \)
(the cumulative fraction of the total variation of \( Y \) (presence of CKD) that can be predicted by the
model) = 0.556, \( R_y^2 \) (explained variance for the \( Y \) component) = 0.902. Of the 202 spots, 47
contributed significantly to the multivariate model and 18 of these were sufficiently large to be picked
from the preparative gel for subsequent identification (Figure 2 and Figure 3C).

Vimentin and alpha-1-microglobulin/bikunin precursor (AMBp) are the most differentially expressed
proteins between CKD and healthy subjects

The 18 adipose tissue protein spots that were significant in the OPLS-DA model and that could be
picked from the preparative gel were identified by LC-MS/MS (Table 2). Four distinct spots differing
slightly in their molecular weight (Figure 2) were identified to be vimentin (annotated vimentin_1-4,
with vimentin_1 having the lowest and vimentin_4 the highest molecular weight). Further analysis was
focused on the two proteins that contributed most strongly to the separation of the control and CKD
groups and that were the most significant in the multivariate model, namely vimentin_1 (expression
lower in CKD) and alpha-1-microglobulin/bikunin precursor (AMBp, expression higher in CKD) (Figure
3B and 3C). Of the other vimentin spots, vimentin_2 was also expressed at lower levels, while
vimentin_3 and vimentin_4 were expressed at higher levels in CKD compared to controls. However,
none of these vimentin spots contributed to the model as strongly as vimentin_1. To confirm
differences in expression of vimentin and AMBP, adipose tissue protein extracts from controls and
CKD patients were analysed by Western blot (Figure 4). In agreement with our 2D-gel results and
data from others revealing multiple vimentin isoforms in human adipose tissue several vimentin
isoforms were also identified by Western blot, as indicated by the multiple bands (Figure 4). In line
with the 2D-gel results, the bands on the Western blots corresponding to the lowest molecular weight
isoforms (similar to vimentin_1 and vimentin_2 on the 2D-gels) had lower expression in the CKD
patients than in controls (visual assessment, Figure 4). Inspection of Western blots also clearly
confirmed that adipose tissue from CKD patients contained more AMBP than healthy controls (Figure
4).

To confirm that the differential expression of vimentin_1 and AMBP proteins was truly related to CKD
as opposed to a consequence of the difference in BMI between the groups (lower in CKD) we
performed an additional analysis using the same healthy controls and a group of 9 morbidly obese
CKD subjects (BMI 41.2±4.4 kg/m²), with greater BMI than the controls and whose adipose tissue had
been analysed by proteomics in an identical fashion. In this new OPLS-DA model (which had model
quality parameters reflecting a robust model: number of principal components = 1+1, Rₓ² = 0.42, Qᵧ² =
0.705, Rᵧ² = 0.907) we found that vimentin_1 expression (spot volume) was significantly lower in
obese patients with CKD and AMBP significantly higher in obese patients with CKD compared to
healthy controls (Supplemental Figure 3). Direct comparison of the adipose tissue spot volumes of
vimentin_1 and AMBP between healthy controls, lean CKD and obese CKD subjects showed
vimentin_1 to be significantly lower (Figure 5A) and AMBP to be significantly higher (Figure 5B) in
both CKD groups compared to the controls. These differences persisted even after correction for BMI,
age and gender (control vs CKD lean: p=0.002 and p=0.0006 for vimentin_1 and AMBP respectively;
control vs CKD obese: p=0.015 and p=0.004 for vimentin_1 and AMBP respectively; data not shown).
Finally, we found no significant correlations between vimentin_1 or AMBP spot volumes and BMI when
all 3 groups (lean CKD patients, slightly overweight controls and morbidly obese CKD patients) were
combined (data not shown). These data suggest that the differential expression of vimentin_1 and
AMBP proteins is indeed driven by the presence of kidney disease rather than by BMI.
Discussion

We have characterised subcutaneous abdominal adipose tissue from lean patients with stage 5 CKD in comparison to healthy subjects and found increased numbers of phagocytic cells (CD68+) and smaller adipocytes in individuals with kidney failure, but no signs of fibrosis. Proteomic analysis revealed different adipose tissue protein profiles between the groups. Our data highlight decreased low molecular weight-vimentin isoforms and increased AMBP protein expression in adipose tissue as particularly important characteristics of uremic fat. To the best of our knowledge this is the first study to combine morphological and immunohistochemical characterisation with proteomic analysis of adipose tissue from patients with kidney disease.

Systemic inflammation is a feature of CKD, but only recently has adipose tissue inflammation been proposed as a potential contributor to the development of cardiovascular complications in CKD.\textsuperscript{22,30} We report here that lean CKD patients have more CD68-positive cells in their adipose tissue than healthy controls, suggesting that adipose inflammation may indeed be a feature of uremic fat. Although adipose tissue fibrosis is a hallmark of perturbed adipose function,\textsuperscript{31,32} we found no differences in the degree of adipose tissue fibrosis, assessed by collagen content, between lean CKD patients and controls. This could mean that either adipose tissue fibrosis is not a feature of kidney disease, or that we were not able to detect fibrosis, which might develop in another adipose tissue depot, or that fibrosis is not very apparent in non-obese individuals. Of interest was the significantly smaller adipocyte size in the lean kidney failure patients compared to controls. Considering the high CVD risk and insulin resistance associated with CKD, one could have expected an increased adipocyte size, which is coupled to blunted insulin signalling in both obese and non-obese individuals.\textsuperscript{33-35} On the other hand, the lean CKD subjects had lower BMI than the controls (although the difference in adipocyte size remained significant after correcting for BMI) and individuals with kidney failure suffer from protein wasting and cachexia,\textsuperscript{36} but this can be expected to affect primarily lean body mass rather than fat. However, perturbed adipose tissue fatty acid metabolism in CKD is indicated by the increased adipocyte lipolysis and reduced lipogenesis that is induced by an uremic milieu.\textsuperscript{19,37} Hence impaired adipose tissue uptake and storage of fatty acids in CKD, which could be reflected in alterations in adipocyte size, could lead to a pro-atherogenic blood lipid profile.
The proteomic analysis confirmed our hypothesis that CKD is associated with alterations in the functionality of adipose tissue. The multivariate analysis revealed that the protein composition of subcutaneous adipose tissue could distinguish between subjects with CKD and healthy controls. We identified several proteins whose expression differed significantly between CKD patients and controls. The two proteins that contributed most to the multivariate model including healthy controls and lean CKD patients were vimentin and AMBP, which were decreased and increased in CKD respectively. Although the lean CKD patients had lower BMI than the controls, we attribute alterations in vimentin and AMBP to the presence of CKD, as opposed to differences in obesity, since these alterations were maintained even after correction for BMI. Furthermore, we also quantified these proteins in a group of morbidly obese patients with CKD. The differences in both vimentin and AMBP between healthy controls and CKD patients were the same irrespective of whether the CKD patients were lean or obese, and their expression in adipose tissue did not correlate with BMI thereby indicating that CKD, rather than obesity, underlies alterations in vimentin and AMBP protein expression in uremic adipose tissue.

Vimentin is a protein present in mesenchymal cells, including adipocytes, with different isoforms that are differentially regulated. Correspondingly, our proteomic analysis identified four protein spots in adipose tissue as vimentin (vimentin_1-4), with molecular weights in line with those reported previously (46-54KDa) and we confirmed this by Western blot. Of all the protein spots with lower expression in the lean CKD patients, vimentin_1 (the lowest molecular weight-vimentin spot) contributed most to the separation of the CKD and control subjects in the multivariate model. Western blot analysis confirmed that the lowest molecular weight isoforms of vimentin differed the most between controls and lean CKD. Vimentin is a lipid-droplet associated protein involved in the regulation of adipocyte lipolysis. Primary human adipocytes cultured with uremic serum show increased basal lipolysis and decreased perilipin expression, indicating that a uremic environment can alter lipid droplet metabolism, with vimentin having a known role in the latter. Moreover, higher vimentin expression is a hallmark of more insulin-sensitive adipose tissue. Thus vimentin plays an important role in adipose tissue function and dysregulation of these processes as a result of alterations in vimentin expression are likely to perturb adipose tissue, promoting cardiovascular events, such as...
Atherosclerosis,\textsuperscript{4} but it remains to be established whether and how different isoforms of vimentin affect human adipose tissue, and whether they are differentially regulated by the uremic milieu.

Another adipose tissue protein that made a major contribution to the separation between the CKD patients and controls in the multivariate models and whose expression was much higher in the CKD patients was AMBP. Although produced mainly in the liver, AMBP protein is also expressed in adipose tissue (www.genecards.org). AMBP is a precursor protein that is cleaved into two functional proteins – alpha-1-microglobulin (A1M) and bikunin – with all the peptide sequences identified in the present mass spectrometry analysis within A1M. Since A1M binds and degrades free radicals and oxidising agents, and oxidative stress in adipose tissue is linked to obesity, inflammation, diabetes and other diseases,\textsuperscript{44,46} the high AMBP protein levels in adipose tissue of CKD patients indicate that the tissue is exposed to the damaging effects of free radicals, which can cause lipid and protein oxidation and cell death, and has a compromised functionality.

We acknowledge some limitations of our study, in particular the small sample size and restriction to subcutaneous adipose tissue. It is possible that alterations in visceral and perivascular adipose tissue depots may have a greater impact on the development of CVD in CKD patients. Finally, the cross-sectional nature of this study restricts our ability to draw causal conclusions. Yet, to the best of our knowledge, this is the first proteomic analysis of adipose tissue from CKD patients therefore we believe it provides relevant information.

In conclusion, we have shown that adipose tissue of patients with CKD has an inflammatory phenotype, has smaller adipocytes and is exposed to oxidative stress, as manifested by high AMBP levels. Furthermore abnormal vimentin expression may affect lipid droplet metabolism and lipolysis rates. These data provide a novel perspective on how changes in adipose tissue could lead to increased risk of cardiovascular events in CKD.
1 Disclosure

2 The Authors have no conflict of interest to declare.

3 Acknowledgements

4 This work received financial support from The Swedish Heart and Lung Foundation, The Swedish Research Council (projects 2015-04622 [RMMB] and 521-2012-1610 [JA]) and Stiftelsen Sigurd och Elsa Goljes Minne. JG was partially supported by faculty funds from the Board of Post-Graduate Education of Karolinska Institutet (KID Award). We would like to thank Professor Peter James and Liselotte Andersson, Department of Immunotechnology, Lund University, for support and technical assistance with the 2D-gel analyses. We also acknowledge Ulrika Jensen, Annika Nilsson and Ann-Christin Emmoth, Njur-KBC, Karolinska University Hospital Huddinge for their help with collecting biopsies.
References


Table 1. Characteristics of the study subjects.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>CKD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (M/F)</td>
<td>11 (3/8)</td>
<td>16 (9/7)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>45.6 ± 8.6</td>
<td>38.8 ± 14.8</td>
</tr>
<tr>
<td>BMI (kg/m^2)</td>
<td>26.2 ± 2.9</td>
<td>22.7 ± 2.1**</td>
</tr>
<tr>
<td>GFR (mL/min)</td>
<td>133 ± 32</td>
<td>12 ± 7**</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>1.0 ± 0.9</td>
<td>7.5 ± 17.9</td>
</tr>
<tr>
<td>Glucose (mmol/L)a</td>
<td>5.2 ± 0.8</td>
<td>5.6 ± 1.0</td>
</tr>
<tr>
<td>Na (mmol/L)</td>
<td>141 ± 1</td>
<td>139 ± 4</td>
</tr>
<tr>
<td>K (mmol/L)</td>
<td>3.9 ± 0.2</td>
<td>4.8 ± 0.7**</td>
</tr>
<tr>
<td>Creatinine (µmol/L)</td>
<td>63 ± 21</td>
<td>742 ± 284**</td>
</tr>
<tr>
<td>Urea (mmol/L)b</td>
<td>4.6 ± 1.2</td>
<td>24.4 ± 9.4**</td>
</tr>
<tr>
<td>Bilirubin (µmol/L)b</td>
<td>7 ± 2</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>ASAT (µkat/L)</td>
<td>0.37 ± 0.07</td>
<td>0.33 ± 0.11</td>
</tr>
<tr>
<td>Leukocytes (x10^9/L)</td>
<td>6.3 ± 1.7</td>
<td>7.6 ± 2.4</td>
</tr>
<tr>
<td>Hemoglobin (g/L)</td>
<td>139 ± 10</td>
<td>113 ± 20**</td>
</tr>
<tr>
<td>Triglyceride (mmol/L)c</td>
<td>N/A</td>
<td>1.7 ± 0.8</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)c</td>
<td>N/A</td>
<td>4.8 ± 1.1</td>
</tr>
<tr>
<td>HDL (mmol/L)c</td>
<td>N/A</td>
<td>1.5 ± 0.6</td>
</tr>
</tbody>
</table>

Values are given as mean ± SD. a data available from 14 CKD subjects; b data available from 12 CKD subjects, c data available from 15 CKD subjects. BMI – body mass index, GFR – glomerular filtration rate [for males GFR = (1.23 x [140 - age] x weight)/serum creatinine; for females GFR = (1.04 x [140 - age] x weight)/serum creatinine], CRP – C-reactive protein (measured with a high sensitivity method), ASAT – aspartate aminotransferase, HDL – high-density lipoprotein cholesterol, N/A – data not available. *p≤0.05, **p≤0.01 for differences between groups (Student’s t-test).
Table 2. Adipose tissue protein spots significant in the OPLS-DA analysis and identified by LC-MS/MS.

<table>
<thead>
<tr>
<th>Protein name</th>
<th>Protein abbreviation</th>
<th>Normalized spot volume Controls</th>
<th>Normalized spot volume CKD</th>
<th>Loading value in OPLS-DA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteins with higher expression in CKD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alpha-1-microglobulin/bikunin precursor</td>
<td>AMBP</td>
<td>0.53±0.13</td>
<td>2.14±0.52**</td>
<td>0.1734</td>
</tr>
<tr>
<td>Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic</td>
<td>GPDA</td>
<td>1.02±0.29</td>
<td>1.67±0.41**</td>
<td>0.1438</td>
</tr>
<tr>
<td>Glyceraldehyde 3-phosphate dehydrogenase</td>
<td>GAPDH</td>
<td>1.10±0.42</td>
<td>1.88±0.59**</td>
<td>0.1438</td>
</tr>
<tr>
<td>Annexin A6</td>
<td>ANXA6</td>
<td>1.09±0.34</td>
<td>2.28±0.70**</td>
<td>0.1399</td>
</tr>
<tr>
<td>Transthyretin</td>
<td>TTHY</td>
<td>1.17±0.43</td>
<td>2.73±0.95**</td>
<td>0.1323</td>
</tr>
<tr>
<td>Alpha-1-antitrypsin_1</td>
<td>A1AT</td>
<td>1.20±0.45</td>
<td>1.78±0.51*</td>
<td>0.1306</td>
</tr>
<tr>
<td>Alpha-1-antitrypsin_2</td>
<td>A1AT</td>
<td>1.16±0.44</td>
<td>1.66±0.46*</td>
<td>0.1259</td>
</tr>
<tr>
<td>14-3-3 protein zeta/delta</td>
<td>1433Z</td>
<td>1.21±0.32</td>
<td>1.74±0.56*</td>
<td>0.1036</td>
</tr>
<tr>
<td>Vimentin_3</td>
<td>VIME</td>
<td>1.49±0.72</td>
<td>2.08±0.82</td>
<td>0.1024</td>
</tr>
<tr>
<td>Vimentin_4</td>
<td>VIME</td>
<td>1.42±0.62</td>
<td>1.91±0.79</td>
<td>0.0971</td>
</tr>
<tr>
<td>Annexin A5_2</td>
<td>ANXA5</td>
<td>1.11±0.54</td>
<td>1.67±0.75</td>
<td>0.0947</td>
</tr>
<tr>
<td>Alpha-1-antitrypsin_3</td>
<td>A1AT</td>
<td>1.42±0.49</td>
<td>1.53±0.50</td>
<td>0.0907</td>
</tr>
<tr>
<td>14-3-3 protein epsilon</td>
<td>1433E</td>
<td>1.20±0.35</td>
<td>1.48±0.42</td>
<td>0.0858</td>
</tr>
<tr>
<td>Serum albumin_2</td>
<td>ALBU</td>
<td>1.13±0.23</td>
<td>1.25±0.18</td>
<td>0.0839</td>
</tr>
</tbody>
</table>
Proteins with lower expression in CKD

<table>
<thead>
<tr>
<th>Protein</th>
<th>VIME</th>
<th>ALBU</th>
<th>ANXA5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vimentin_1</td>
<td>1.58±0.26</td>
<td>0.94±0.28**</td>
<td>-0.1675</td>
</tr>
<tr>
<td>Vimentin_2</td>
<td>1.29±0.56</td>
<td>0.68±0.35**</td>
<td>-0.1372</td>
</tr>
<tr>
<td>Serum albumin_1</td>
<td>2.52±1.05</td>
<td>1.31±0.54**</td>
<td>-0.1140</td>
</tr>
<tr>
<td>Annexin A5_1</td>
<td>2.15±1.38</td>
<td>0.95±0.77*</td>
<td>-0.1003</td>
</tr>
</tbody>
</table>

In cases where two or more spots were identified as the same protein, spots are distinguished by successive numbering (eg vimentin_1, vimentin_2 etc).

*p≤0.05, **p≤0.01 for differences between groups (Student's t-test).
Figure legends

Figure 1. Representative staining for CD68 in subcutaneous adipose tissue sections from (A) a healthy control and (B) a lean CKD patient. Positive (brown) staining indicated with arrows. Scale bar 20µm, magnification 40x. (C) Infiltration of CD68-positive inflammatory cells (number of positive cells per 10mm² tissue area) in adipose tissue of control subjects (n=9, black fill) and patients with CKD (n=14, blue fill). *p<0.05 for differences between the groups. (D) Comparison of collagen content in adipose tissue of controls (n=10, black fill) and CKD patients (n=14, blue fill). (E) Adipocyte size comparison between controls (n=9, black fill) and patients with kidney failure (n=13, blue fill). The average number of cells counted was 71 ± 34 per individual. **p<0.01 for differences between the groups (Mann-Whitney U-test). Box plots represent median (within-box line), minimum and maximum values (whiskers).

Figure 2. Representative 2 dimensional gels (Cy5 labelled) of an adipose tissue protein extract from a control individual (A) and a lean patient with CKD (B). The isoelectric point range is 3-10, non-linear. Spots that were statistically significant in the OPLS-DA model and that were picked for identification are marked in yellow. Spots that were not significant in the model and were identified are marked in pink. 1433E – 14-3-3 protein epsilon, 1433G – 14-3-3 protein gamma, 1433Z – 14-3-3 protein zeta/delta, A1AT – alpha-1-antitrypsin, ACTB – actin, cytoplasmic 1, ALBU – serum albumin, ALDH1A1 – retinal dehydrogenase 1, AMBP – alpha-1-microglobulin/bikunin precursor, APOAIV – apolipoprotein AIV, ANXA5 – annexin A5, ANXA6 – annexin A6, CA1 – carbonic anhydrase 1, FABP4 – fatty acid binding protein 4, GAPDH – glyceraldehyde-3-phosphate dehydrogenase, GPDH – glycerol-3-phosphate dehydrogenase, GSTP1 – glutathione S-transferase P, HBA1 – hemoglobin subunit alpha, HBB – hemoglobin subunit beta, IGHG1 – Ig gamma-1 chain C, PRDX2 – peroxiredoxin 2, TTHY – transthyretin, VIME – vimentin.

Figure 3. OPLS-DA analysis of protein spot volumes of adipose tissue from controls and lean patients with CKD. The presence or absence of CKD was used as the Y vector. The analysis was performed on 7 control individuals, 13 CKD patients and 202 protein spots. The Hotelling’s T2 (based on 95% confidence level) tolerance ellipse is shown in the score plot (A), which shows all the individuals analyzed (controls yellow, CKD patients blue). Predictive loadings representing the analyzed protein...
spots are presented as a scatter plot for all protein spots (B) and as a column plot for spots that were identified and were significant in the model (C). In (B) and (C) vimentin_1 and AMBP are marked in red. For protein name abbreviations, see legend to Figure 2. The significance of the differentially expressed spots was calculated as the difference between the absolute value of the loadings (ABS[loading]) and the absolute value of the corresponding jack-knife confidence interval (ABS[CI]). A positive difference indicates significance.

Figure 4. Western blot for vimentin and AMBP in adipose tissue from controls (n=7) and lean CKD patients (n=13). Beta actin was used as loading control. Half the CKD samples and all the control samples were run on one gel and the other half of the CKD samples and the same control samples were run on a second gel (space restrictions prevented the loading of all samples on one gel). Blots of the control samples are shown only once for ease of understanding. AMBP is consistently higher in the CKD patients, while the lower molecular weight forms of vimentin are generally lower in the CKD patients as compared to controls (visual assessment).

Figure 5. Comparison of (A) vimentin_1 and (B) AMBP spot volumes between controls (n=7, black fill), lean CKD patients (n=13, light blue fill) and obese CKD patients (n=9, dark blue fill). *p≤0.05, **p≤0.01 for differences between the groups (ANOVA followed by Fisher’s LSD post-hoc tests). Box plots represent median (within-box line), minimum and maximum values (whiskers).

Supplemental Figure 1. Representative images of picrosirius red collagen staining of subcutaneous adipose tissue sections from a control individual (A) and a lean CKD patient (B). Positive staining (red) is visible between adipocytes as reticular fibers as well as clusters of thicker collagen bundles. Scale bar = 20µm.

Supplemental Figure 2. Representative images of transformed ImageJ pictures of subcutaneous adipose tissue sections from a control individual (A) and a lean CKD patient (B) used for calculation of adipocyte size.

Supplemental Figure 3. OPLS-DA analysis of protein spot volumes of adipose tissue from healthy controls and obese patients with CKD. The presence or absence of CKD was used as the Y vector. The analysis was performed on 7 control individuals, 9 obese CKD patients and 202 protein spots.
The Hotelling’s T² (based on 95% confidence level) tolerance ellipse is shown in the score plot (A), which shows all the individuals analyzed (controls yellow, CKD patients blue). Predictive loadings representing the analyzed protein spots are presented as a scatter plot for all protein spots (B). Vimentin_1 and AMBP are marked in red.
Figure 1

A. Adipocyte size (µm²)

B. Collagen (% total area)

C. CD68-positive cells/10cm²

D. Control vs. CKD

E. Adipocyte size (µm²)

**Figure 1**

Legend:

- **A**: Adipocyte size measurement
- **B**: Collagen percentage in the tissue
- **C**: CD68-positive cells per 10 cm²
- **D**: Comparative analysis between Control and CKD
- **E**: Adipocyte size distribution

**Statistical Tests**

- ***:** Significant difference between groups
- ****: Highly significant difference between groups
Figure 2
Figure 3

Panel A shows a scatter plot with three clusters, indicating different groups or categories.

Panel B displays a biplot with the Vimentin_1 and AMBP variables highlighted.

Panel C presents a loading value bar chart for various variables, including AMBP.
Figure 4

_____ Control ______  ______________ CKD ____________ ___

Vimentin

AMBP

Actin